Stage IV lung cancer patients may benefit from targeting tumor sites with radiation or surgery after initial treatment, according to new results from a multicenter, randomized, controlled phase II study. The findings were presented last week at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
Researchers previously reported encouraging results for progression-free survival (PFS), which were published in The Lancet Oncology in 2016. The trial was closed prematurely, ...
Stage IV lung cancer patients may benefit from targeting tumor sites with radiation or surgery after initial treatment, according to new results from a multicenter, randomized, controlled phase II study. The findings were presented last week at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
Researchers previously reported encouraging results for progression-free survival (PFS), which were published in The Lancet Oncology in 2016. The trial was closed prematurely, ...